Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
2.930
-0.270 (-8.44%)
At close: Oct 1, 2026, 4:00 PM EDT
2.960
+0.030 (1.02%)
After-hours: Oct 1, 2026, 7:30 PM EDT
Adagene Employees
Adagene had 128 employees as of December 31, 2025. The number of employees decreased by 10 or -7.25% compared to the previous year.
Employees
128
Change (1Y)
-10
Growth (1Y)
-7.25%
Revenue / Employee
$72,584
Profits / Employee
-$160,242
Market Cap
196.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 128 | -10 | -7.25% |
| Dec 31, 2024 | 138 | -36 | -20.69% |
| Dec 31, 2023 | 174 | -74 | -29.84% |
| Dec 31, 2022 | 248 | -11 | -4.25% |
| Dec 31, 2021 | 259 | 61 | 30.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Foghorn Therapeutics | 106 |
| Alector | 103 |
| Keros Therapeutics | 92 |
| Cartesian Therapeutics | 75 |
| Compugen | 75 |
| Anavex Life Sciences | 34 |
| Eledon Pharmaceuticals | 33 |
ADAG News
- 9 days ago - Adagene announces China’s NMPA approved IND for ADG138 - TheFly
- 9 days ago - Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager - GlobeNewsWire
- 15 days ago - Adagene Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 16 days ago - Adagene Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 21 days ago - Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - GlobeNewsWire
- 21 days ago - Adagene initiated with a Buy at Chardan - TheFly
- 22 days ago - Adagene announces $2M milestone payment from Exelixis - TheFly
- 22 days ago - Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates - GlobeNewsWire